



Clinical trial results:

A Randomized, Double-Blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma

Summary

EudraCT number	2011-002424-41
Trial protocol	DE ES IT
Global end of trial date	20 November 2014

Results information

Result version number	v1 (current)
This version publication date	07 July 2016
First version publication date	07 July 2016

Trial information

Trial identification

Sponsor protocol code	OGX-427-02
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01454089
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	OncoGenex Technologies Inc
Sponsor organisation address	1001 W Broadway, Suite 400, Vancouver, BC, Canada, V6H 4B1
Public contact	Director, Regulatory Affairs, OncoGenex Technologies Inc , 001 425-686-1500,
Scientific contact	Director, Regulatory Affairs, OncoGenex Technologies Inc , 001 425-686-1500,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 November 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 November 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 arm to control arm; 1000 mg OGX-427 arm to control arm; and pooled 600 mg and 1000 mg OGX-427 arms to control arm.

Protection of trial subjects:

Each subject was provided an informed consent form that was reviewed and approved by the site's governing Institutional Review Board (IRB), Research Ethics Board (REB) or Ethics Committee (EC). The Principal Investigator (or designee) provided potential subjects with a verbal description of the study, including but not limited to, study purpose and study procedures, risks and benefits and answered all subject questions prior to signing the form.

Because Grade 1 and 2 constitutional symptoms (e.g. chills, fever, pruritus, flushing) are seen in the majority of patients during the loading-dose infusions, all subjects were premedicated with an H2 blocker, antihistamine and corticosteroid during the loading doses and Cycle 1, (Days 1, 8 and 15), at a minimum.

Background therapy:

Subjects received gemcitabine (1000 mg/m²) administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m²) was administered IV. Carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must have occurred within 5 days of the third loading dose of Study Drug. Chemotherapy treatment on this schedule continued for up to six cycles or until disease progression or unacceptable toxicity.

Evidence for comparator: -

Actual start date of recruitment	01 October 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	France: 23
Country: Number of subjects enrolled	Germany: 16
Country: Number of subjects enrolled	Italy: 7
Country: Number of subjects enrolled	Poland: 28
Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	United States: 44
Worldwide total number of subjects	179
EEA total number of subjects	111

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	92
From 65 to 84 years	87
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study included a 28-day Screening period. Of the 256 subjects screened, 3 died, 59 did not meet inclusion/exclusion criteria, and 11 withdrew consent. Of the 183 subjects randomized, 179 received at least 1 dose of study drug.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo + Gem/Cis

Arm description:

Subjects received 3 loading doses of placebo within a 9-day period. Following the loading dose period, participants received weekly placebo infusions intravenously (IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received each dose of Study Drug as a 2-hour infusion.

Arm title	OGX-427 600 mg + Gem/Cis
------------------	--------------------------

Arm description:

Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Arm type	Experimental
Investigational medicinal product name	OGX-427
Investigational medicinal product code	OGX-427
Other name	apatorsen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received each dose of Study Drug as a 2-hour infusion.

Arm title	OGX-427 1000 mg + Gem/Cis
------------------	---------------------------

Arm description:

Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Arm type	Experimental
Investigational medicinal product name	OGX-427
Investigational medicinal product code	OGX-427
Other name	apatorsen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received each dose of Study Drug as a 2-hour infusion.

Number of subjects in period 1	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis
Started	61	58	60
Entered Chemotherapy Period	60	55	56
Completed 6 Cycles of Chemotherapy	21 ^[1]	21 ^[2]	12 ^[3]
Entered Maintenance Period	38 ^[4]	33	28 ^[5]
Completed	39	29	35
Not completed	22	29	25
Consent withdrawn by subject	1	3	3
Study Terminated by Sponsor	20	23	22
Lost to follow-up	1	3	-

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 21 subjects completed all 6 cycles of chemotherapy.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 21 subjects completed all 6 cycles of chemotherapy.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 12 subjects completed all 6 cycles of chemotherapy.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 38 subjects entered the maintenance period (not all completed 6 cycles of chemotherapy).

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 28 subjects entered the maintenance period (not all completed 6 cycles of chemotherapy).

Baseline characteristics

Reporting groups

Reporting group title	Placebo + Gem/Cis
-----------------------	-------------------

Reporting group description:

Subjects received 3 loading doses of placebo within a 9-day period. Following the loading dose period, participants received weekly placebo infusions intravenously (IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group title	OGX-427 600 mg + Gem/Cis
-----------------------	--------------------------

Reporting group description:

Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group title	OGX-427 1000 mg + Gem/Cis
-----------------------	---------------------------

Reporting group description:

Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis
Number of subjects	61	58	60
Age, Customized			
Units: participants			
< 65 Years	32	25	35
≥ 65 Years	29	33	25
Age Continuous			
Units: years			
arithmetic mean	62.7	65	63.4
standard deviation	± 9.2	± 6.5	± 8.9
Gender, Male/Female			
Units: participants			
Female	9	7	15
Male	52	51	45
Karnofsky Performance Status (KPS)			
KPS quantifies a participant's general well-being and activities of daily life and participants were classified based on their functional impairment. An 11-level score, KPS score ranges between 0 (death) to 100 (no evidence of disease) percent. Higher score means higher ability to perform daily tasks.			
Units: Subjects			
≥ 80%	55	53	54
< 80%	6	5	6
Visceral Disease			
Presence of visceral metastases (defined as documented disease in lung, liver, and/or bone).			
Units: Subjects			
No	18	25	18
Yes	43	33	42
Baseline Circulating Tumor Cell (CTC) Count			
Participants with a baseline assessment (n=45, 45, 48 for the 3 arms, respectively).			
Units: Subjects			

0 cells	28	26	27
1 to < 5 cells	5	11	8
5 to 20 cells	6	5	5
21 to 50 cells	5	2	2
> 50 cells	1	1	6
No assessment	16	13	12
Age, Customized Units: Subjects			
< 75 Years	55	56	54
≥ 75 Years	6	2	6

Reporting group values	Total		
Number of subjects	179		
Age, Customized Units: participants			
< 65 Years	92		
≥ 65 Years	87		
Age Continuous Units: years arithmetic mean standard deviation	-		
Gender, Male/Female Units: participants			
Female	31		
Male	148		
Karnofsky Performance Status (KPS)			
KPS quantifies a participant's general well-being and activities of daily life and participants were classified based on their functional impairment. An 11-level score, KPS score ranges between 0 (death) to 100 (no evidence of disease) percent. Higher score means higher ability to perform daily tasks.			
Units: Subjects			
≥ 80%	162		
< 80%	17		
Visceral Disease			
Presence of visceral metastases (defined as documented disease in lung, liver, and/or bone).			
Units: Subjects			
No	61		
Yes	118		
Baseline Circulating Tumor Cell (CTC) Count			
Participants with a baseline assessment (n=45, 45, 48 for the 3 arms, respectively).			
Units: Subjects			
0 cells	81		
1 to < 5 cells	24		
5 to 20 cells	16		
21 to 50 cells	9		
> 50 cells	8		
No assessment	41		
Age, Customized Units: Subjects			
< 75 Years	165		
≥ 75 Years	14		

End points

End points reporting groups

Reporting group title	Placebo + Gem/Cis
Reporting group description: Subjects received 3 loading doses of placebo within a 9-day period. Following the loading dose period, participants received weekly placebo infusions intravenously (IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m ² IV on Days 1 and 8) and cisplatin (70 mg/m ² IV on Day 1).	
Reporting group title	OGX-427 600 mg + Gem/Cis
Reporting group description: Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m ² IV on Days 1 and 8) and cisplatin (70 mg/m ² IV on Day 1).	
Reporting group title	OGX-427 1000 mg + Gem/Cis
Reporting group description: Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, subjects received weekly OGX-427 infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Subjects received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m ² IV on Days 1 and 8) and cisplatin (70 mg/m ² IV on Day 1).	
Subject analysis set title	Total OGX-427 + Gem/Cis
Subject analysis set type	Full analysis
Subject analysis set description: Subjects received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, participants received weekly OGX-427 infusions (600 mg or 1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Participants received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m ² IV on Days 1 and 8) and cisplatin (70 mg/m ² IV on Day 1).	

Primary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description: OS is defined as the time from randomization to death from any cause; OS was censored on date of last contact for participants still alive at the time of analysis.	
End point type	Primary
End point timeframe: Baseline to date of death by any cause (up to approximately 3 years)	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: days				
median (confidence interval 95%)	456 (357 to 589)	467 (326 to 705)	474 (350 to 583)	474 (362 to 674)

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo + Gem/Cis v OGX-427 600 mg + Gem/Cis
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.252 ^[1]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.856
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.355

Notes:

[1] - One-sided p-value from stratified log-rank tests.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo + Gem/Cis v OGX-427 1000 mg + Gem/Cis
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.32 ^[2]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.898
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.572
upper limit	1.41

Notes:

[2] - One-sided p-value from stratified log-rank tests.

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo + Gem/Cis v Total OGX-427 + Gem/Cis
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.234 ^[3]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.867
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.588
upper limit	1.277

Notes:

[3] - One-sided p-value from stratified log-rank tests.

Secondary: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs (SAEs), and Grade 3 or Higher AEs

End point title	Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs (SAEs), and Grade 3 or Higher AEs
-----------------	--

End point description:

AE=any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the administration, at any dose, of study drug, whether or not considered related to that product. SAE=any untoward medical occurrence that (at any dose): results in death; is life-threatening; requires inpatient hospital admission or prolongs existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; or other important medical event. Treatment-emergent AEs=AE that occurred after the first dose of study drug up to 30 days after the last dose of study drug. AEs were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment-emergent AEs could have occurred during loading dose period, chemotherapy period, maintenance period, and treatment period. A detailed summary of adverse events is located in the Reported Adverse Event Module.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug to 30 days after last dose of study drug (safety reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: participants				
number (not applicable)				
Treatment-emergent AE	61	58	60	118
Treatment-emergent SAE	26	31	37	68
Treatment-emergent AE Grade 3 or Higher	54	54	58	112

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With at ≥ 1 Hematology Abnormality and ≥ 1 Grade 3 or Higher Hematology Abnormality

End point title	Number of Participants With at ≥ 1 Hematology Abnormality and ≥ 1 Grade 3 or Higher Hematology Abnormality
-----------------	--

End point description:

Hematology abnormalities occurring after the first dose of study drug. Multiple occurrences of an event within a subject were counted only once, as the highest grade. Toxicity grading based on the NCI-CTCAE, Version 4.0.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug to 30 days after last dose of study drug (safety reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: participants				
number (not applicable)				
Any Abnormality	61	56	58	114
Any Grade 3 or Higher Abnormality	39	45	51	96
Anemia	61	56	58	114
Grade 3 or Higher Anemia	23	24	28	52
Leukopenia	47	43	48	91
Grade 3 or Higher Leukopenia	17	17	25	42
Lymphopenia	43	46	44	90
Grade 3 or Higher Lymphopenia	16	15	19	34
Neutropenia	46	39	44	83
Grade 3 or Higher Neutropenia	26	28	34	62
Thrombocytopenia	45	39	45	84
Grade 3 or Higher Thrombocytopenia	13	17	22	39

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With ≥ 1 Serum Chemistry Laboratory Abnormality and ≥ 1 Grade 3 or Higher Serum Chemistry Laboratory Abnormality

End point title	Number of Participants With ≥ 1 Serum Chemistry Laboratory Abnormality and ≥ 1 Grade 3 or Higher Serum Chemistry Laboratory Abnormality
-----------------	---

End point description:

Chemistry laboratory abnormalities occurring after the first dose of study drug. Multiple occurrences of an event within a participant were counted only once, as the highest grade. Toxicity grading based on NCI-CTCAE, Version 4.0. 'Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT)' is a derived parameter, and includes participants with elevations in ALT or AST or both.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug to 30 days after last dose of study drug (safety reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: participants				
number (not applicable)				
Any Abnormality	60	56	58	114

Any Grade 3 or Higher Abnormality	36	35	30	65
Elevated ALT	33	31	29	60
Grade 3 or Higher Elevated ALT	2	1	1	2
Elevated AST	27	15	20	35
Grade 3 or Higher Elevated AST	1	2	1	3
Elevated AST or ALT	39	33	32	65
Grade 3 or Higher Elevated AST or ALT	2	2	1	3
Elevated Alkaline Phosphatase	25	26	28	54
Grade 3 or Higher Elevated Alkaline Phosphatase	3	1	1	2
Elevated Creatinine	27	37	38	75
Grade 3 or Higher Elevated Creatinine	2	3	2	5
Hyperbilirubinemia	8	6	4	10
Grade 3 or Higher Hyperbilirubinemia	0	3	0	3
Hypercalcemia	16	20	13	33
Grade 3 or Higher Hypercalcemia	1	0	0	0
Hyperkalemia	30	22	21	43
Grade 3 or Higher Hyperkalemia	4	1	2	3
Hypermagnesemia	3	7	6	13
Grade 3 or Higher Hypermagnesemia	0	0	1	1
Hypernatremia	4	2	2	4
Grade 3 or Higher Hypernatremia	0	0	0	0
Hyperuricemia	27	18	20	38
Grade 3 or Higher Hyperuricemia	27	18	20	38
Hypoalbuminemia	36	36	40	76
Grade 3 or Higher Hypoalbuminemia	1	3	1	4
Hypocalcemia	24	19	23	42
Grade 3 or Higher Hypocalcemia	3	1	0	1
Hypokalemia	14	15	17	32
Grade 3 or Higher Hypokalemia	5	6	3	9
Hypomagnesemia	31	32	34	66
Grade 3 or Higher Hypomagnesemia	2	1	3	4
Hyponatremia	42	42	42	84
Grade 3 or Higher Hyponatremia	4	11	12	23
Hypophosphatemia	27	25	23	48
Grade 3 or Higher Hypophosphatemia	3	5	3	8

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With ≥ 1 Urinalysis Abnormality

End point title	Number of Participants With ≥ 1 Urinalysis Abnormality
-----------------	---

End point description:

Urinalysis abnormalities occurring after the first dose of study drug. Multiple occurrences of an event within a participant were counted only once, as the highest grade. Each '+' indicates a higher order of magnitude of abnormal protein present in the urine.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug to 30 days after last dose of study drug (safety reporting period ranged

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: participants				
number (not applicable)				
Any Abnormality	56	57	57	114
Erythrocytes, Any	51	52	53	105
Erythrocytes, Trace	16	16	11	27
Erythrocytes, Moderate	19	22	14	36
Erythrocytes, Large	16	14	28	42
Protein, Any	50	51	49	100
Protein, Trace	7	9	9	18
Protein, +	21	20	21	41
Protein, ++	13	15	11	26
Protein, +++	8	5	5	10
Protein, ++++	1	2	3	5

Statistical analyses

No statistical analyses for this end point

Secondary: Confirmed Best Objective Tumor Response

End point title	Confirmed Best Objective Tumor Response
End point description:	
Complete Response (CR)=complete disappearance of all measurable and non-measurable disease with no new lesions. Any pathological lymph node (target or non-target) must have a reduction in short axis to < 10 mm). All markers of disease must have normalized. Partial Response (PR)=a decrease from baseline of $\geq 30\%$ of the diameter(s) of all target measurable lesions with no unequivocal progression of non-measurable lesions and no new lesions. Stable Disease (SD)=does not qualify for CR, PR, or progression. Disease Progression (PD)=if at least one of following criteria is met: appearance of any new lesion or site of disease; a 20% increase in the sum of the diameter(s) of target measurable lesions over either the smallest sum observed or over baseline if no decrease during therapy has occurred (the sum must also demonstrate an absolute increase of at least 5 mm); or unequivocal progression of non-target lesions alone.	
End point type	Secondary
End point timeframe:	
Baseline to measured progressive disease (up to approximately 3 years)	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: participants				
number (not applicable)				
CR	4	5	7	12
PR	33	28	23	51
SD	11	11	13	24
PD	9	11	9	20
Not Done	4	3	8	11

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR) and Disease Control Rate

End point title	Overall Response Rate (ORR) and Disease Control Rate
End point description:	
Participants were defined as having an "overall response" if their best response was either confirmed CR, confirmed PR, unconfirmed CR or unconfirmed PR. ORR was defined as the percent of participants who had an overall response. Participants were defined as having "disease control" if their best response was confirmed CR, confirmed PR, unconfirmed CR, unconfirmed PR or SD. The disease control rate (DCR) was defined as the percent of participants with disease control. (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.)	
End point type	Secondary
End point timeframe:	
Baseline to measured progressive disease (up to approximately 3 years)	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61	58	60	118
Units: percentage of participants				
number (not applicable)				
Overall Response Rate	61	57	50	53
Disease Control Rate	79	76	72	74

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Overall Response Rate	
Comparison groups	Placebo + Gem/Cis v OGX-427 600 mg + Gem/Cis

Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3513
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	1.51

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Overall Response Rate	
Comparison groups	Placebo + Gem/Cis v OGX-427 1000 mg + Gem/Cis
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2542
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	1.37

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo + Gem/Cis v Total OGX-427 + Gem/Cis
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2353
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.35
upper limit	1.29

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Disease Control Rate	
Comparison groups	Placebo + Gem/Cis v OGX-427 600 mg + Gem/Cis
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4129
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	1.75

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Disease Control Rate	
Comparison groups	Placebo + Gem/Cis v OGX-427 1000 mg + Gem/Cis
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3951
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	1.63

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Disease Control Rate	
Comparison groups	Placebo + Gem/Cis v Total OGX-427 + Gem/Cis

Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.381
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	1.54

Secondary: Duration of ORR

End point title	Duration of ORR
End point description:	
Duration of response is defined as the duration from the first overall response to the first event of SD or PD, whichever happened first. (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.) If no SD or PD, the participant was censored at the last tumor assessment (prior to other anti-cancer therapy if applicable).	
End point type	Secondary
End point timeframe:	
Baseline to measured progressive disease (up to approximately 3 years)	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	37 ^[4]	33 ^[5]	28 ^[6]	61 ^[7]
Units: days				
median (confidence interval 95%)	156 (112 to 254)	259 (140 to 357)	218 (154 to 342)	245 (173 to 299)

Notes:

[4] - subjects with an overall response

[5] - subjects with an overall response

[6] - subjects with an overall response

[7] - subjects with an overall response

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS)
End point description:	
PFS was defined as the time from randomization to the date of disease progression or death, whichever occurred first, before or after treatment discontinuation. For participants still on study and those who remained alive and had not progressed after treatment discontinuation, PFS was censored on the date of the last tumor assessment.	
End point type	Secondary

End point timeframe:

Baseline to measured progressive disease (up to approximately 12 months)

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61 ^[8]	58 ^[9]	60 ^[10]	118 ^[11]
Units: days				
median (confidence interval 95%)	189 (148 to 242)	227 (183 to 301)	228 (150 to 270)	227 (183 to 252)

Notes:

[8] - Number of subjects with progression or death=49

[9] - Number of subjects with progression or death=40

[10] - Number of subjects with progression or death=40

[11] - Number of subjects with progression or death=80

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo + Gem/Cis v OGX-427 600 mg + Gem/Cis
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.198
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.539
upper limit	1.278

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo + Gem/Cis v OGX-427 1000 mg + Gem/Cis
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.366
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.927
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.433

Statistical analysis title	Statistical Analysis 3
Comparison groups	Placebo + Gem/Cis v Total OGX-427 + Gem/Cis
Number of subjects included in analysis	179
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.222
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.867
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.601
upper limit	1.251

Secondary: Change From Baseline in Serum Hsp27 levels by End of Treatment

End point title	Change From Baseline in Serum Hsp27 levels by End of Treatment
End point description: Post-baseline observations that did not have a corresponding baseline observation were excluded. End-of-treatment is last non-hemolyzed observation up to last dose + 30 days. Hemolyzed samples were excluded.	
End point type	Secondary
End point timeframe: Baseline to 30 days after last dose of study drug (reporting period ranged from approximately 30 days to 850 days).	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	58 ^[12]	53 ^[13]	56 ^[14]	109 ^[15]
Units: µg/L				
arithmetic mean (standard deviation)				
Baseline	8.6 (± 8.3)	10.5 (± 13.4)	9.9 (± 12.5)	10.2 (± 12.9)
Minimum Post-baseline Value	4.3 (± 4.7)	5.4 (± 10.9)	4.1 (± 5.1)	4.7 (± 8.5)
Change From Baseline	-4.3 (± 8)	-5.1 (± 13.6)	-5.8 (± 13.5)	-5.5 (± 13.5)

Notes:

[12] - Subjects with an assessment

[13] - Subjects with an assessment

[14] - Subjects with an assessment

[15] - Subjects with an assessment

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Serum Clusterin Levels by End of Treatment

End point title	Change From Baseline in Serum Clusterin Levels by End of Treatment
-----------------	--

End point description:

Post-baseline observations that did not have a corresponding Baseline observation were excluded. End of Treatment is last observation up to last dose + 30 days.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to 30 days after last dose of study drug (reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	57 ^[16]	52 ^[17]	54 ^[18]	106 ^[19]
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline	54.7 (± 22.5)	56.7 (± 18.9)	52 (± 10.5)	54.3 (± 15.3)
Minimum Post-baseline Value	43.2 (± 9)	44.4 (± 9.3)	48.2 (± 10.5)	46.3 (± 10.1)
Change From Baseline	-11.5 (± 21.8)	-12.3 (± 18.9)	-3.9 (± 9.8)	-8 (± 15.5)

Notes:

[16] - Subjects with an assessment

[17] - Subjects with an assessment

[18] - Subjects with an assessment

[19] - Subjects with an assessment

Statistical analyses

No statistical analyses for this end point

Secondary: Baseline to Last Post-baseline Shift in Circulating Tumor Cell (CTC) Count

End point title	Baseline to Last Post-baseline Shift in Circulating Tumor Cell (CTC) Count
-----------------	--

End point description:

Number of participants with baseline to last post-baseline shifts in 1 of 4 categories: from < 5 cells/7.5 mL at baseline to < 5 cells/7.5 mL at last post-baseline; from < 5 cells/7.5 mL at baseline to ≥ 5 cells/7.5 mL at last post baseline; from ≥ 5 cells/7.5 mL at baseline to < 5 cells/7.5 mL at last post-baseline; or from ≥ 5 cells/7.5 mL at baseline to ≥ 5 cells/7.5 mL at last post baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of treatment (reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	40 ^[20]	38 ^[21]	38 ^[22]	76 ^[23]
Units: cells/7.5 mL				
number (not applicable)				
< 5 cells/7.5 mL to < 5 cells/7.5 mL	28	30	28	58
< 5 cells/7.5 mL to ≥ 5 cells/7.5 mL	2	2	0	2
≥ 5 cells/7.5 mL to < 5 cells/7.5 mL	7	5	10	15
≥ 5 cells/7.5 mL to ≥ 5 cells/7.5 mL	3	1	0	1

Notes:

[20] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[21] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[22] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[23] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

Statistical analyses

No statistical analyses for this end point

Secondary: Baseline to Last Post-baseline Change in CTC Count

End point title	Baseline to Last Post-baseline Change in CTC Count
-----------------	--

End point description:

Number of participants with baseline to last post-baseline changes in 1 of 3 categories: Decrease from baseline; Increase from baseline, No change from baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of treatment (reporting period ranged from approximately 30 days to 850 days).

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	40 ^[24]	38 ^[25]	38 ^[26]	76 ^[27]
Units: cells/7.5 mL				
number (not applicable)				
Decrease	13	12	15	27
Increase	8	11	2	13
No change	19	15	21	36

Notes:

[24] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[25] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[26] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

[27] - Subjects with both a baseline and end-of-treatment (last on-treatment observation) result

Statistical analyses

No statistical analyses for this end point

Secondary: Serum OGX-427 Maximum Plasma Concentration (C_{max}) and Trough Levels

End point title	Serum OGX-427 Maximum Plasma Concentration (Cmax) and Trough Levels
End point description: EOT=end-of-treatment	
End point type	Secondary
End point timeframe: Baseline to 30 days after last dose of study drug (reporting period ranged from approximately 30 days to 850 days).	

End point values	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis	Total OGX-427 + Gem/Cis
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	61 ^[28]	58 ^[29]	60 ^[30]	118 ^[31]
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1: Trough; n=51, 45, 46, 91	0.5 (± 3.2)	36 (± 32)	32.6 (± 25.5)	34.3 (± 28.8)
Cycle 1 Day 1: Cmax; n=50, 46, 39, 85	0.7 (± 4.8)	62788.6 (± 34408.1)	100526.2 (± 52571.8)	80103.5 (± 47353.5)
Cycle 2 Day 1: Trough; n=42, 41, 34, 75	0 (± 0)	28.7 (± 23.7)	27.6 (± 12.7)	28.2 (± 19.4)
Cycle 2 Day 1: Cmax; n=40, 33, 31, 64	0 (± 0)	77830.9 (± 34463)	103200 (± 25588.7)	90119.1 (± 32838.5)
Cycle 3 Day 1: Trough; n=41, 35, 31, 66	0 (± 0)	36.3 (± 37.5)	31.1 (± 13.7)	33.9 (± 28.8)
Cycle 3 Day 1: Cmax; n=37, 36, 31, 67	0 (± 0)	77244.4 (± 36242.2)	116687.1 (± 48446.8)	95494 (± 46433.2)
Cycle 4 Day 1: Trough; n=41, 35, 29, 64	0 (± 0)	23.6 (± 6.2)	38.6 (± 33.5)	30.4 (± 24)
Cycle 4 Day 1: Cmax; n=41, 37, 29, 66	0 (± 0)	77613.5 (± 25373.7)	109062.1 (± 35939.9)	91431.8 (± 34064.1)
Cycle 5 Day 1: Trough; n=36, 28, 25, 53	0 (± 0)	26.1 (± 11.1)	36.6 (± 26.2)	31.1 (± 20.2)
Cycle 5 Day 1: Cmax; n=36, 29, 26, 55	0.6 (± 3.8)	72751.7 (± 24798.4)	118319.2 (± 62796.8)	94292.7 (± 51688.2)
Cycle 6 Day 1: Trough; n=30, 24, 17, 41	0 (± 0)	26.7 (± 13.1)	38.4 (± 34)	31.5 (± 24.4)
Cycle 6 Day 1: Cmax; n=29, 23, 17, 40	0 (± 0)	76474.7 (± 46557)	125144.7 (± 63888.3)	97159.5 (± 59084.5)
EOT: Trough; n=34, 31, 31, 62	2.4 (± 13.9)	25.2 (± 11.1)	29.4 (± 24)	27.3 (± 18.7)

Notes:

[28] - n=subjects with assessment at given time point

[29] - n=subjects with assessment at given time point

[30] - n=subjects with assessment at given time point

[31] - n=subjects with assessment at given time point

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug to 30 days after last dose of study drug (safety reporting period ranged from approximately 30 days to 850 days).

Adverse event reporting additional description:

Events reported are treatment-emergent adverse events, defined as events which have a start date on or after the date of first study treatment administration and not more than 30 days after the date of the last study treatment administration.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

Reporting groups

Reporting group title	Placebo + Gem/Cis
-----------------------	-------------------

Reporting group description:

Participants received 3 loading doses of placebo within a 9-day period. Following the loading dose period, participants received weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle. Participants received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group title	OGX-427 600 mg + Gem/Cis
-----------------------	--------------------------

Reporting group description:

Participants received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, participants received weekly OGX-427 infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Participants received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group title	OGX-427 1000 mg + Gem/Cis
-----------------------	---------------------------

Reporting group description:

Participants received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, participants received weekly OGX-427 infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Participants received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Reporting group title	Total OGX-427 + Gem/Cis
-----------------------	-------------------------

Reporting group description:

Participants received 3 loading doses of 600 mg OGX-427 within a 9-day period. Following the loading dose period, participants received weekly OGX-427 infusions (600 mg or 1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle. Participants received chemotherapy consisting of up to 6 cycles of gemcitabine (1000 mg/m² IV on Days 1 and 8) and cisplatin (70 mg/m² IV on Day 1).

Serious adverse events	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 61 (42.62%)	31 / 58 (53.45%)	37 / 60 (61.67%)
number of deaths (all causes)	41	34	37
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour invasion			

subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	2 / 61 (3.28%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 61 (1.64%)	3 / 58 (5.17%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	2 / 2	2 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 1
Asthenia			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Death			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Device occlusion			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multi-organ failure			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pain			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Epididymitis			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pelvic pain			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	2 / 61 (3.28%)	3 / 58 (5.17%)	3 / 60 (5.00%)
occurrences causally related to treatment / all	0 / 3	2 / 3	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	3 / 61 (4.92%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			

subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Chronic inflammatory demyelinating polyradiculoneuropathy			

subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolitic cerebral infarction			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	2 / 61 (3.28%)	3 / 58 (5.17%)	4 / 60 (6.67%)
occurrences causally related to treatment / all	0 / 3	1 / 3	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 61 (1.64%)	2 / 58 (3.45%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 2	0 / 2	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			

subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 61 (1.64%)	4 / 58 (6.90%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	3 / 60 (5.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	2 / 61 (3.28%)	1 / 58 (1.72%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 2	0 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	3 / 61 (4.92%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	1 / 3	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Ascites			

subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic pseudo-obstruction			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis intestinalis			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 61 (0.00%)	2 / 58 (3.45%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis chronic			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	3 / 60 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure acute			

subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Muscular weakness			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteolysis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	2 / 61 (3.28%)	1 / 58 (1.72%)	8 / 60 (13.33%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 61 (1.64%)	2 / 58 (3.45%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 1	1 / 2	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 61 (1.64%)	3 / 58 (5.17%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	3 / 3	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 61 (4.92%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract abscess			
subjects affected / exposed	0 / 61 (0.00%)	1 / 58 (1.72%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium colitis			
subjects affected / exposed	1 / 61 (1.64%)	0 / 58 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			

subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	3 / 60 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 61 (1.64%)	1 / 58 (1.72%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 58 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Total OGX-427 + Gem/Cis		
Total subjects affected by serious adverse events			
subjects affected / exposed	68 / 118 (57.63%)		
number of deaths (all causes)	71		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour invasion			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tumour pain			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	4 / 118 (3.39%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Sudden death			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	1 / 2		
Asthenia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Device occlusion			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperthermia			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Multi-organ failure			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pain			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Epididymitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Prostatitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic pain			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		

Dyspnoea			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood creatinine increased			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Foot fracture			

subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Chronic inflammatory demyelinating polyradiculoneuropathy			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Embolic cerebral infarction			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolic encephalopathy			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Epilepsy			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemiparesis			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord compression			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences causally related to treatment / all	2 / 7		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	4 / 118 (3.39%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	5 / 118 (4.24%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		

Nausea				
subjects affected / exposed	3 / 118 (2.54%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	3 / 118 (2.54%)			
occurrences causally related to treatment / all	2 / 4			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	2 / 118 (1.69%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	2 / 118 (1.69%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Anal fistula				
subjects affected / exposed	1 / 118 (0.85%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Ascites				
subjects affected / exposed	1 / 118 (0.85%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Colonic pseudo-obstruction				
subjects affected / exposed	1 / 118 (0.85%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	1 / 118 (0.85%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Ileitis				

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumatosis intestinalis			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct obstruction			

subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cholecystitis chronic			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperbilirubinaemia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	4 / 118 (3.39%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal failure acute			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
Hydronephrosis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal impairment			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract obstruction			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Osteolysis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pathological fracture			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Back pain			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	9 / 118 (7.63%)		
occurrences causally related to treatment / all	1 / 13		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	4 / 118 (3.39%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis salmonella			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract abscess			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridium colitis			
subjects affected / exposed	0 / 118 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo + Gem/Cis	OGX-427 600 mg + Gem/Cis	OGX-427 1000 mg + Gem/Cis
Total subjects affected by non-serious adverse events			
subjects affected / exposed	61 / 61 (100.00%)	57 / 58 (98.28%)	59 / 60 (98.33%)
Vascular disorders			
Hypertension			
subjects affected / exposed	10 / 61 (16.39%)	16 / 58 (27.59%)	12 / 60 (20.00%)
occurrences (all)	17	22	16
Flushing			
subjects affected / exposed	2 / 61 (3.28%)	1 / 58 (1.72%)	5 / 60 (8.33%)
occurrences (all)	2	1	6
Thrombophlebitis			
subjects affected / exposed	0 / 61 (0.00%)	4 / 58 (6.90%)	2 / 60 (3.33%)
occurrences (all)	0	4	2
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	28 / 61 (45.90%)	26 / 58 (44.83%)	25 / 60 (41.67%)
occurrences (all)	79	78	68
Pyrexia			
subjects affected / exposed	10 / 61 (16.39%)	18 / 58 (31.03%)	22 / 60 (36.67%)
occurrences (all)	14	38	33
Fatigue			
subjects affected / exposed	20 / 61 (32.79%)	18 / 58 (31.03%)	20 / 60 (33.33%)
occurrences (all)	40	42	36
Oedema peripheral			
subjects affected / exposed	11 / 61 (18.03%)	19 / 58 (32.76%)	18 / 60 (30.00%)
occurrences (all)	16	21	25
Chills			
subjects affected / exposed	2 / 61 (3.28%)	9 / 58 (15.52%)	14 / 60 (23.33%)
occurrences (all)	3	15	19

Chest pain subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 3	4 / 58 (6.90%) 5	7 / 60 (11.67%) 9
Pain subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 3	3 / 58 (5.17%) 5	3 / 60 (5.00%) 3
Reproductive system and breast disorders Pelvic pain subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	3 / 58 (5.17%) 4	5 / 60 (8.33%) 6
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	10 / 61 (16.39%) 12	13 / 58 (22.41%) 15	11 / 60 (18.33%) 12
Dyspnoea subjects affected / exposed occurrences (all)	12 / 61 (19.67%) 15	12 / 58 (20.69%) 14	12 / 60 (20.00%) 16
Pulmonary embolism subjects affected / exposed occurrences (all)	7 / 61 (11.48%) 7	5 / 58 (8.62%) 6	3 / 60 (5.00%) 3
Epistaxis subjects affected / exposed occurrences (all)	6 / 61 (9.84%) 9	3 / 58 (5.17%) 3	4 / 60 (6.67%) 4
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	8 / 61 (13.11%) 9	12 / 58 (20.69%) 20	7 / 60 (11.67%) 9
Anxiety subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 3	3 / 58 (5.17%) 4	6 / 60 (10.00%) 7
Depression subjects affected / exposed occurrences (all)	4 / 61 (6.56%) 4	2 / 58 (3.45%) 2	5 / 60 (8.33%) 5
Investigations Weight decreased			

subjects affected / exposed occurrences (all)	6 / 61 (9.84%) 7	4 / 58 (6.90%) 4	10 / 60 (16.67%) 12
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	10 / 61 (16.39%)	10 / 58 (17.24%)	15 / 60 (25.00%)
occurrences (all)	11	15	16
Neuropathy peripheral			
subjects affected / exposed	6 / 61 (9.84%)	11 / 58 (18.97%)	14 / 60 (23.33%)
occurrences (all)	6	14	23
Paraesthesia			
subjects affected / exposed	7 / 61 (11.48%)	10 / 58 (17.24%)	8 / 60 (13.33%)
occurrences (all)	8	14	14
Headache			
subjects affected / exposed	4 / 61 (6.56%)	9 / 58 (15.52%)	7 / 60 (11.67%)
occurrences (all)	5	13	8
Dizziness			
subjects affected / exposed	5 / 61 (8.20%)	10 / 58 (17.24%)	5 / 60 (8.33%)
occurrences (all)	7	12	9
Peripheral sensory neuropathy			
subjects affected / exposed	3 / 61 (4.92%)	4 / 58 (6.90%)	2 / 60 (3.33%)
occurrences (all)	4	5	2
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	33 / 61 (54.10%)	29 / 58 (50.00%)	31 / 60 (51.67%)
occurrences (all)	92	81	75
Anaemia			
subjects affected / exposed	27 / 61 (44.26%)	25 / 58 (43.10%)	32 / 60 (53.33%)
occurrences (all)	64	59	95
Thrombocytopenia			
subjects affected / exposed	21 / 61 (34.43%)	25 / 58 (43.10%)	24 / 60 (40.00%)
occurrences (all)	51	82	65
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	6 / 61 (9.84%)	5 / 58 (8.62%)	6 / 60 (10.00%)
occurrences (all)	7	6	6
Gastrointestinal disorders			

Nausea			
subjects affected / exposed	40 / 61 (65.57%)	31 / 58 (53.45%)	37 / 60 (61.67%)
occurrences (all)	88	74	70
Constipation			
subjects affected / exposed	22 / 61 (36.07%)	25 / 58 (43.10%)	23 / 60 (38.33%)
occurrences (all)	31	33	38
Vomiting			
subjects affected / exposed	25 / 61 (40.98%)	20 / 58 (34.48%)	19 / 60 (31.67%)
occurrences (all)	42	34	36
Diarrhoea			
subjects affected / exposed	21 / 61 (34.43%)	16 / 58 (27.59%)	22 / 60 (36.67%)
occurrences (all)	24	32	33
Abdominal pain			
subjects affected / exposed	8 / 61 (13.11%)	12 / 58 (20.69%)	13 / 60 (21.67%)
occurrences (all)	11	16	14
Dyspepsia			
subjects affected / exposed	4 / 61 (6.56%)	8 / 58 (13.79%)	8 / 60 (13.33%)
occurrences (all)	5	10	8
Abdominal pain upper			
subjects affected / exposed	3 / 61 (4.92%)	5 / 58 (8.62%)	6 / 60 (10.00%)
occurrences (all)	4	5	12
Abdominal distension			
subjects affected / exposed	3 / 61 (4.92%)	5 / 58 (8.62%)	4 / 60 (6.67%)
occurrences (all)	4	5	5
Stomatitis			
subjects affected / exposed	3 / 61 (4.92%)	4 / 58 (6.90%)	4 / 60 (6.67%)
occurrences (all)	3	4	5
Abdominal pain lower			
subjects affected / exposed	6 / 61 (9.84%)	3 / 58 (5.17%)	3 / 60 (5.00%)
occurrences (all)	8	4	4
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	6 / 61 (9.84%)	7 / 58 (12.07%)	11 / 60 (18.33%)
occurrences (all)	9	8	11
Rash			

subjects affected / exposed occurrences (all)	5 / 61 (8.20%) 6	10 / 58 (17.24%) 14	8 / 60 (13.33%) 14
Pruritus subjects affected / exposed occurrences (all)	5 / 61 (8.20%) 5	8 / 58 (13.79%) 9	8 / 60 (13.33%) 9
Erythema subjects affected / exposed occurrences (all)	4 / 61 (6.56%) 4	3 / 58 (5.17%) 4	4 / 60 (6.67%) 4
Renal and urinary disorders Renal impairment subjects affected / exposed occurrences (all)	21 / 61 (34.43%) 69	24 / 58 (41.38%) 71	28 / 60 (46.67%) 72
Haematuria subjects affected / exposed occurrences (all)	7 / 61 (11.48%) 15	6 / 58 (10.34%) 8	16 / 60 (26.67%) 25
Dysuria subjects affected / exposed occurrences (all)	2 / 61 (3.28%) 4	4 / 58 (6.90%) 8	6 / 60 (10.00%) 10
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	15 / 61 (24.59%) 25	13 / 58 (22.41%) 16	23 / 60 (38.33%) 68
Pain in extremity subjects affected / exposed occurrences (all)	8 / 61 (13.11%) 11	11 / 58 (18.97%) 11	9 / 60 (15.00%) 12
Muscle spasms subjects affected / exposed occurrences (all)	1 / 61 (1.64%) 1	6 / 58 (10.34%) 9	8 / 60 (13.33%) 12
Arthralgia subjects affected / exposed occurrences (all)	5 / 61 (8.20%) 10	4 / 58 (6.90%) 6	9 / 60 (15.00%) 10
Flank pain subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 5	2 / 58 (3.45%) 2	6 / 60 (10.00%) 9
Muscular weakness			

subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 3	4 / 58 (6.90%) 5	3 / 60 (5.00%) 6
Musculoskeletal pain subjects affected / exposed occurrences (all)	2 / 61 (3.28%) 2	4 / 58 (6.90%) 6	3 / 60 (5.00%) 4
Bone pain subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 4	2 / 58 (3.45%) 4	4 / 60 (6.67%) 7
Infections and infestations			
Urinary tract infection subjects affected / exposed occurrences (all)	18 / 61 (29.51%) 34	15 / 58 (25.86%) 19	16 / 60 (26.67%) 22
Upper respiratory tract infection subjects affected / exposed occurrences (all)	7 / 61 (11.48%) 7	7 / 58 (12.07%) 9	2 / 60 (3.33%) 2
Bronchitis subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 4	4 / 58 (6.90%) 5	3 / 60 (5.00%) 3
Respiratory tract infection subjects affected / exposed occurrences (all)	5 / 61 (8.20%) 5	1 / 58 (1.72%) 1	5 / 60 (8.33%) 6
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	19 / 61 (31.15%) 28	18 / 58 (31.03%) 26	18 / 60 (30.00%) 29
Hypomagnesaemia subjects affected / exposed occurrences (all)	10 / 61 (16.39%) 23	9 / 58 (15.52%) 18	10 / 60 (16.67%) 22
Hypokalaemia subjects affected / exposed occurrences (all)	8 / 61 (13.11%) 13	8 / 58 (13.79%) 16	6 / 60 (10.00%) 9
Hyponatraemia subjects affected / exposed occurrences (all)	4 / 61 (6.56%) 6	6 / 58 (10.34%) 6	8 / 60 (13.33%) 18
Hyperglycaemia			

subjects affected / exposed	2 / 61 (3.28%)	7 / 58 (12.07%)	3 / 60 (5.00%)
occurrences (all)	2	21	5
Hyperuricaemia			
subjects affected / exposed	4 / 61 (6.56%)	5 / 58 (8.62%)	2 / 60 (3.33%)
occurrences (all)	5	7	2
Hypophosphataemia			
subjects affected / exposed	1 / 61 (1.64%)	4 / 58 (6.90%)	2 / 60 (3.33%)
occurrences (all)	1	6	3

Non-serious adverse events	Total OGX-427 + Gem/Cis		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	116 / 118 (98.31%)		
Vascular disorders			
Hypertension			
subjects affected / exposed	28 / 118 (23.73%)		
occurrences (all)	38		
Flushing			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	7		
Thrombophlebitis			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	6		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	51 / 118 (43.22%)		
occurrences (all)	146		
Pyrexia			
subjects affected / exposed	40 / 118 (33.90%)		
occurrences (all)	71		
Fatigue			
subjects affected / exposed	38 / 118 (32.20%)		
occurrences (all)	78		
Oedema peripheral			
subjects affected / exposed	37 / 118 (31.36%)		
occurrences (all)	46		
Chills			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Chest pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>23 / 118 (19.49%)</p> <p>34</p> <p>11 / 118 (9.32%)</p> <p>14</p> <p>6 / 118 (5.08%)</p> <p>8</p>		
<p>Reproductive system and breast disorders</p> <p>Pelvic pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 118 (6.78%)</p> <p>10</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pulmonary embolism</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Epistaxis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>24 / 118 (20.34%)</p> <p>27</p> <p>24 / 118 (20.34%)</p> <p>30</p> <p>8 / 118 (6.78%)</p> <p>9</p> <p>7 / 118 (5.93%)</p> <p>7</p>		
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Anxiety</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Depression</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>19 / 118 (16.10%)</p> <p>29</p> <p>9 / 118 (7.63%)</p> <p>11</p> <p>7 / 118 (5.93%)</p> <p>7</p>		
Investigations			

Weight decreased subjects affected / exposed occurrences (all)	14 / 118 (11.86%) 16		
Nervous system disorders			
Dysgeusia subjects affected / exposed occurrences (all)	25 / 118 (21.19%) 31		
Neuropathy peripheral subjects affected / exposed occurrences (all)	25 / 118 (21.19%) 37		
Paraesthesia subjects affected / exposed occurrences (all)	18 / 118 (15.25%) 28		
Headache subjects affected / exposed occurrences (all)	16 / 118 (13.56%) 21		
Dizziness subjects affected / exposed occurrences (all)	15 / 118 (12.71%) 21		
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 7		
Blood and lymphatic system disorders			
Neutropenia subjects affected / exposed occurrences (all)	60 / 118 (50.85%) 156		
Anaemia subjects affected / exposed occurrences (all)	57 / 118 (48.31%) 154		
Thrombocytopenia subjects affected / exposed occurrences (all)	49 / 118 (41.53%) 147		
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	11 / 118 (9.32%) 12		
Gastrointestinal disorders			

Nausea			
subjects affected / exposed	68 / 118 (57.63%)		
occurrences (all)	144		
Constipation			
subjects affected / exposed	48 / 118 (40.68%)		
occurrences (all)	71		
Vomiting			
subjects affected / exposed	39 / 118 (33.05%)		
occurrences (all)	70		
Diarrhoea			
subjects affected / exposed	38 / 118 (32.20%)		
occurrences (all)	65		
Abdominal pain			
subjects affected / exposed	25 / 118 (21.19%)		
occurrences (all)	30		
Dyspepsia			
subjects affected / exposed	16 / 118 (13.56%)		
occurrences (all)	18		
Abdominal pain upper			
subjects affected / exposed	11 / 118 (9.32%)		
occurrences (all)	17		
Abdominal distension			
subjects affected / exposed	9 / 118 (7.63%)		
occurrences (all)	10		
Stomatitis			
subjects affected / exposed	8 / 118 (6.78%)		
occurrences (all)	9		
Abdominal pain lower			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	8		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	18 / 118 (15.25%)		
occurrences (all)	19		
Rash			

subjects affected / exposed	18 / 118 (15.25%)		
occurrences (all)	28		
Pruritus			
subjects affected / exposed	16 / 118 (13.56%)		
occurrences (all)	18		
Erythema			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	8		
Renal and urinary disorders			
Renal impairment			
subjects affected / exposed	52 / 118 (44.07%)		
occurrences (all)	143		
Haematuria			
subjects affected / exposed	22 / 118 (18.64%)		
occurrences (all)	33		
Dysuria			
subjects affected / exposed	10 / 118 (8.47%)		
occurrences (all)	18		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	36 / 118 (30.51%)		
occurrences (all)	84		
Pain in extremity			
subjects affected / exposed	20 / 118 (16.95%)		
occurrences (all)	23		
Muscle spasms			
subjects affected / exposed	14 / 118 (11.86%)		
occurrences (all)	21		
Arthralgia			
subjects affected / exposed	13 / 118 (11.02%)		
occurrences (all)	16		
Flank pain			
subjects affected / exposed	8 / 118 (6.78%)		
occurrences (all)	11		
Muscular weakness			

subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	11		
Musculoskeletal pain			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	10		
Bone pain			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	11		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	31 / 118 (26.27%)		
occurrences (all)	41		
Upper respiratory tract infection			
subjects affected / exposed	9 / 118 (7.63%)		
occurrences (all)	11		
Bronchitis			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	8		
Respiratory tract infection			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	7		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	36 / 118 (30.51%)		
occurrences (all)	55		
Hypomagnesaemia			
subjects affected / exposed	19 / 118 (16.10%)		
occurrences (all)	40		
Hypokalaemia			
subjects affected / exposed	14 / 118 (11.86%)		
occurrences (all)	25		
Hyponatraemia			
subjects affected / exposed	14 / 118 (11.86%)		
occurrences (all)	24		
Hyperglycaemia			

subjects affected / exposed	10 / 118 (8.47%)		
occurrences (all)	26		
Hyperuricaemia			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	9		
Hypophosphataemia			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	9		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported